PL3712162T3 - MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE - Google Patents

MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE

Info

Publication number
PL3712162T3
PL3712162T3 PL18875727.2T PL18875727T PL3712162T3 PL 3712162 T3 PL3712162 T3 PL 3712162T3 PL 18875727 T PL18875727 T PL 18875727T PL 3712162 T3 PL3712162 T3 PL 3712162T3
Authority
PL
Poland
Prior art keywords
smac mimetics
iap inhibitors
mimetics used
iap
inhibitors
Prior art date
Application number
PL18875727.2T
Other languages
English (en)
Inventor
Yingchun Liu
Zhaobing XU
Lihong Hu
Charles Z. Ding
Xingxun ZHU
Guoping Hu
Jian Li
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Publication of PL3712162T3 publication Critical patent/PL3712162T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL18875727.2T 2017-11-13 2018-11-13 MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE PL3712162T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711117079 2017-11-13
PCT/CN2018/115256 WO2019091492A1 (zh) 2017-11-13 2018-11-13 用作iap抑制剂的smac模拟物及其用途

Publications (1)

Publication Number Publication Date
PL3712162T3 true PL3712162T3 (pl) 2022-11-14

Family

ID=66438734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18875727.2T PL3712162T3 (pl) 2017-11-13 2018-11-13 MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE

Country Status (16)

Country Link
US (1) US11358950B2 (pl)
EP (1) EP3712162B1 (pl)
JP (1) JP7257397B2 (pl)
KR (1) KR102707188B1 (pl)
CN (2) CN114685602A (pl)
AU (1) AU2018364218B2 (pl)
BR (1) BR112020009369A2 (pl)
CA (1) CA3082437A1 (pl)
DK (1) DK3712162T3 (pl)
EA (1) EA202091169A1 (pl)
ES (1) ES2927195T3 (pl)
IL (1) IL274598B2 (pl)
PL (1) PL3712162T3 (pl)
SG (1) SG11202004377XA (pl)
WO (1) WO2019091492A1 (pl)
ZA (1) ZA202003178B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936126A4 (en) * 2019-03-07 2022-12-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINATION OF IAP INHIBITOR AND IMMUNOCHECK POINT INHIBITOR
KR20220006611A (ko) * 2019-05-10 2022-01-17 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서의 smac 모방물의 결정 및 그 제조방법
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3
WO2025082431A1 (zh) * 2023-10-18 2025-04-24 正大天晴药业集团股份有限公司 一种吲哚衍生物治疗头颈部肿瘤的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2253614T3 (da) 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Iap의 억제제
DK1836201T4 (da) * 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
NZ577150A (en) * 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
CA2712604A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
NO2755614T3 (pl) * 2012-01-03 2018-03-31
US9353419B2 (en) 2012-05-04 2016-05-31 Novartis Ag Biomarkers for IAP inhibitor therapy

Also Published As

Publication number Publication date
CN114685602A (zh) 2022-07-01
BR112020009369A2 (pt) 2020-10-13
KR102707188B1 (ko) 2024-09-13
EA202091169A1 (ru) 2020-08-06
SG11202004377XA (en) 2020-06-29
EP3712162A4 (en) 2021-08-04
IL274598B1 (en) 2024-09-01
IL274598A (en) 2020-06-30
CN111247161A (zh) 2020-06-05
ES2927195T3 (es) 2022-11-03
KR20200081456A (ko) 2020-07-07
CA3082437A1 (en) 2019-05-16
AU2018364218A1 (en) 2020-06-04
DK3712162T3 (da) 2022-09-19
WO2019091492A1 (zh) 2019-05-16
JP7257397B2 (ja) 2023-04-13
EP3712162B1 (en) 2022-08-24
CN111247161B (zh) 2021-12-31
US11358950B2 (en) 2022-06-14
EP3712162A1 (en) 2020-09-23
ZA202003178B (en) 2022-10-26
IL274598B2 (en) 2025-01-01
JP2021502397A (ja) 2021-01-28
US20210371400A1 (en) 2021-12-02
AU2018364218B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
IL270330B (en) Beta-lactamase inhibitors and their uses
IL271275B1 (en) Preparations containing croons and their uses
GB201605126D0 (en) Inhibitors and their uses
EP3234244A4 (en) Fiberball batting and articles comprising the same
ZA201802236B (en) Combination antibacterial composition and short-course antibacterial regimen
EP3271502A4 (en) Multi-layered microfibers and use thereof
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
EP3112411A4 (en) Glove and glove composition
HUE063848T2 (hu) LSD1 gátlók és gyógyászati alkalmazásaik
ZA202003178B (en) Smac mimetics used as iap inhibitors and use thereof
EP3133153A4 (en) Novel bacteriophage and composition comprising same
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
EP3133151A4 (en) Novel bacteriophage and composition comprising same
GB202004930D0 (en) Composition and uses thereof
GB2584009B (en) Aminoglycosides and uses thereof
SG11202102182VA (en) Desiccant composition and use thereof
EP3135761A4 (en) Novel bacteriophage and composition comprising same
GB2566894B (en) Herbicide composition comprising clomazone and use thereof
GB201901591D0 (en) Herbicide composition comprising clomazone and use thereof
PL3307080T3 (pl) Środek słodzący oraz jego zastosowanie
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
IL266659B (en) fgfr4 inhibitor, a pharmaceutical preparation containing it and its use
IL252660A0 (en) Compounds characterized by an inverse freezing property and their uses
IL248576A0 (en) Anti-lice preparation and its uses